

Memorandum

- To: Members of the Accessibility and Affordability Working Group
- From: Rosa Canet-Avilés, PhD. CSO and Interim Patient Access Team Lead, Shyam Patel, Associate Vice President Preclinical Development, and Joseph Gold, PhD. Senior Director Clinical Development
- Re: Access and Affordability (A&A) Implementation in Preclinical and Clinical Development programs

Date: 04/30/2025

BACKGROUND

The CIRM team, in collaboration with the Access and Affordability Working Group (AAWG), is charged with developing and assisting with the implementation of financial models to support the accessibility and affordability of treatments and cures arising from institute-funded research for Californians.¹ Pursuant to this charge, CIRM has worked closely with the AAWG and its chair to identify opportunities to enhance access to clinical trials and resulting products generally. To that end, to date, the AAWG has recommended the establishment of the CIRM Patient Support Program² and the Community Care Centers of Excellence.³

In August 2024, the AAWG evaluated a range of health economics, access planning, and policy options to inform the implementation of CIRM's Strategic Allocation Framework (SAF)—a datadriven model for prioritizing resource allocation to maximize the agency's impact during the remaining years of the Strategic Plan. The AAWG was asked to consider potential access and reimbursement strategies for late-stage clinical trials and approved therapies. During the meeting, the working group endorsed CIRM's proposed strategic aim: that every CIRM-funded project completing a late-stage clinical trial must have a clear, feasible strategy to enable access and affordability for all California patients, particularly those from underserved populations.

AAWG members considered and discussed a variety of implementation options, including incorporating value-based pricing and health economic analyses into access plans, incentivizing scalable manufacturing technologies, and fostering strategic partnerships with Medi-Cal, cancer centers, and community-based networks. They emphasized the need for a staged approach—beginning with early signals around cost and manufacturability in preclinical and early clinical stages, while requiring robust access strategies in late-stage development. Members also highlighted the importance of involving health economists in program design, exploring alignment with California legislation such as the Cancer Care Equity Act, and ensuring that access strategies are adaptable, measurable, and grounded in health equity.

In response to the AAWG recommendations, CIRM engaged a broad set of expert stakeholders across academia, industry and policy to identify potential partners with the expertise to support the development of this accessibility and affordability framework for incorporation into CIRM's

¹ The California Stem Cell Research, Treatments, and Cures Initiative of 2020 Section: *125290.75. Treatments and Cures Accessibility and Affordability Working Group*

² https://www.cirm.ca.gov/agendas/07222022-august-accessibility-and-affordability-working-group/

³ https://www.cirm.ca.gov/agendas/march-10-accessibility-and-affordability-working-group-meeting/



research and development programs. Through this outreach process, CIRM received three strong proposals and ultimately selected BlueRidge Life Sciences to develop tools and methodologies aimed at enhancing accessibility and affordability of CIRM-funded therapies. The goal is to support thoughtful planning across CIRM's preclinical and clinical-stage programs to ensure that innovative treatments reach the patients who need them most. Over the past few months, through this collaborative partnership we have develop a draft framework for this purpose.

OBJECTIVE

The objective of this discussion is for the AAWG to review and provide input on the draft tools developed to support access and affordability planning across CIRM's preclinical and clinical-stage funding programs. These tools include:

- A **checklist** of key activities related to access, affordability, and payer readiness, tailored by development stage and activity type.
- A **rubric** for evaluating access planning during application review and award management, supporting consistent, transparent decision-making.
- **Guidance documents** to help applicants understand expectations, available support, and best practices.

The above tools are designed to provide structure and clarity for applicants and reviewers while remaining flexible to accommodate scientific and programmatic considerations. The AAWG's input will help ensure these materials are appropriate, actionable and aligned with the evolving healthcare landscape.

TOOLKIT COMPONENTS

- 1. The Checklist (see Appendix A and B for details) outlines key commercialization-related activities across four functional areas that may directly or indirectly influence patient access and affordability of cell and gene therapies:
 - a. Market Access
 - b. Commercialization
 - c. Health Economics and Outcomes Research (HEOR)
 - d. Medical Affairs

Each activity is categorized based on its importance at different stages of development (preclinical to Phase 3/BLA) and is marked as:

- Must Have
- Should Have
- Nice to Have

Activities are also classified as either **pre-requisite** (to be addressed before application) or **milestone** (to be addressed during the course of the award). The checklist ensures applicants are thinking early and proactively about the practical elements that determine whether a successful therapy ultimately reaches patients.

2. To support transparency and consistency in review, an **Evaluation Rubric** (see Appendix A and B for details) has been developed for evaluating applicants' access and commercialization planning:



- Preclinical applications will be reviewed by the Grants Working Group (GWG) using the rubric
- Clinical-stage applications will be reviewed by the GWG in consultation with external experts in HEOR and commercialization, particularly as complexity increases with development phase

Each activity will be assigned a raw score by the reviewers contributing to a **composite score** that reflects readiness and feasibility of access planning. This scoring model supports transparent evaluation and informed decision-making.

The feedback received during the review will be used both at the time of application and, where relevant, for setting award milestones and monitoring.

3. Guidance Documents (see Appendix C)

Accompanying materials will help applicants, reviewers, and staff align on expectations. These include:

- Definitions of each checklist activity
- Examples of phase-appropriate implementation
- Recommendations for documentation and milestone planning
- Best practices for patient access and affordability integration

These resources are being finalized and will be included in application materials for future PDEV and CLIN2 rounds.

IMPLEMENTATION PLAN

The toolkit will be piloted in the upcoming rounds of PDEV and CLIN2 programs, with internal staff and reviewers trained on its use. Awardees will be expected to achieve stage-appropriate milestones aligned with the checklist, with award monitoring to ensure progress.

To ensure transparency and support adoption, we are considering:

- A public-facing webinar for applicants
- Ongoing refinement of tools based on user feedback

Requested Action: We respectfully request that the AAWG review and approve the proposed toolkit, including the checklist, evaluation rubric, and guidance documents, to enable implementation of access and affordability planning in CIRM's Preclinical Development (PDEV) and Clinical Stage (CLIN2) funding programs. Your endorsement will support consistent application of these materials across CIRM's portfolio and reinforce our shared commitment to ensuring Californians can access the innovative treatments we help move forward.

for Commercia Scr	herapy (CGTx) Checklist alization Activities and arring Tool		Directions: Cells in a light <u>orange</u> color () may l 1) Select Stage of development (Cell B3). 2) Optional: Filter the respective development st 3) Select Activity Score (Colum N).	be updated by user. All other cells to be left unchanged. age (column J, K, L or M) for non blank cells.				Priority Level Key	Low (Nice to Have)	Medium (Should Have)	High (Must Have)	Scoring System 0=Not started 1=Reasonably planned 2=In process/partially completed			
Pre-clinical			Sy deleter Adamsy obsite (dolatini 14).						\bigcirc			3=Completed but insufficient 4=Completed but needs updating			
Timing of	Activity name	Activity Owner	Activity description	Benefits of undertaking activity	Barriers to executing activity	Overcoming barriers	Supports Access/Affordability		Timing			5=Completed in last 12 months Raw Score	Raw Score Weighting	Level of Priority	Weighted Score
activity	Market landscape assessment/market research	Market Access		Understanding schrift 8 Understanding he size of the market, potential customers, unnet needs, and potential barriers to entry.	The cost of preclinical market research can be perceived as prohibitively expensive and very time consuming for small companies or start-ups and often there is only one person in the company with	Perform in-house research reaching out to providers/payers/advocacy groups, and other key stakeholders. Utilize free online industry reports to inform market assessment. Consider minimal investment options for acquiring therapeutic	Access/Affordability Possible	Pre-clinical	Phase 1	Phase 2	Phase 3	0	0	2	0
Pre-clinical/1/2/3	Reimbursement and market access strategy	Market Access	Planning for the product's reimbursement strategy by assessing the healthcare landscape, payer preferences, and pricing		Accessing reliable, evidence including real-world data to inform pricing and reimbursement decisions can be challenging.										
			models.		as not having codes required for diagnosis and reimbursement.	Conduct early pricing studies to understand the price corridor that might be acceptable from the perspective of payers and providers given the attributes of the TPP. Early engagement with payers to understand access turdles (e.g., prior autorizations): understand impacts the new product might have on provider practice in order to facilitate adoption.	Yes					2	0.4	1	0.4
Phase 1/2/3	Factor and and	Communicipation	Develop early market and revenue forecasts	These analyses are refined throughout the	F	Continue monitoring and refinement of strategy as the product goes through the development process. Document key assumptions for early forecasts that are									
Phase 1/2/3	Early revenue and market forecast	Commercialization	Develop early market and revenue forecasts using published evidence and qualitative primary research to understand the target population, peak market share, pricing and resulting revenues.	These analyses are refined throughout the development process and useful to regolating potential licensing agreements.	Early torecasts will be rutimentary, and largely based on crude hypothecial assumptions, More robust forecasts require an evidence-based understanding of the therapeutic area, available treatments, and where the asset fits in the clinical paradigm. Additionally, insights are needed to understand potential market shares and pricing assumptions.	Document key assumptions for saity forecasts that are developed influors. These assumptions can be validated or refined during ubscream, the same and the same and Refine forecasts during the chical development cycle by conducting robust secondary and primary market research using the TPP, understand where the product fis into the chical paradigm, and gain heights from Dis regarding how the product with be proceived; product market and price regul-	Possible					2	0.4	0	0
Phase1/2/3		Commercialization	Starting the process of brand development,	Lay the foundation for future value message	Early product positioning will be largely hypothesis	Work with a market access/strategy consulting firm with expertise in developing forecasts. Ensure market research is executed highlighting where the									
	positioning		incluting naming and positioning the drug in the marketplace. Understand how a product is differentiated in the market.	 development and what drivers of value are important to physicians, patients, payers and other stakeholders. Attract funding to support future development. 	driven given the lack of available/robust evidence. Not understanding the product's place in the clinical paradigm, potential value to patients, payers and providers. As the product nears the end of phase 3 clinical studies, the branding wilb dedpendent on competing the value message development activity.	product files into the clinical paradigm; research with payers and providers will give nsight into how the product will be perceived. Early in the development process, setablish a clear vision for the product outlining the unnet need and how the product will meet the need. Later in the development process, develop a brand strategy that identifies the target patients/providers, define the brand by what messages are to be communicated, and lately develop a	Possible					2	0.4	0	0
Phase1/2/3	Market segmentation	Market Access	Segregate potential customers (e.g., patients/providers/payers) into groups based on different characteristics (e.g., geography,	Key benefits include the ability to optimize marketing effort, enhance adoption and brand competitiveness.	Lack of data to be able to look at geography, demographics, and behaviors of the different stakeholders.	positioning statement. This activity will require the value message development to be completed. Identify datasets that allow for identification of site of service and HCP prescribing behaviors.	Yes					2	0.4	0	0
Phase2/3	Establish (clinical and payer) advisory board	Commercialization	advisers. Periodically seek feedback on clinica	s Clinical and payer KOLs offer expert advice as the al development program progresses through the clinical stages of development through commercial launch.	of multiple advisors with busy schedules.	Develop logistics to follow relevant company and local rules and laws when organizing an advisory board meeting.									
			Periodically develop content for advisors to review and provide feedback to support the development process.		KOLs will need independent contractor agreements (incl CDAs) and the sponsor will need to report on honoraria, travel, accommodation and other expenses for compliance reasons. Shared materials typically require legal approval of content and attendee ratios.	Consider outsourcing the organization, logistics, agenda, content development and meeting out-put analysis/reporting to a contractor to assist unless in-house company support is available.	Possible					2	0.4	0	0
Phase2/3	Value message	Market Access	Develop value messages that communicate key drivers of value, which is supported by evidence that help differentiate a therapeutic in the markeplace.	Value messages help clearly communicate the benefits of a drug to various stakeholders, including reactions of the second state of the second state of the ensure that second states are the respective and economic value of the drug.	Ensure the meeting meets objectives. Not incorporating key stakeholder input early in the evidence generation process (i.e. Yhase I), so that. Phase 2 and pivotal triats comtain the right data to support a strong value proposition. At the frontend of the development process a TPP is developed to begin formulating the key benefits and areas of differentiation for a drug. It is essential to have developed the key data to support each value message in parallel with the clinical development process.	Conduct early market research (i.e. pre-clinical or Phase 1) into the market landscape, unmet needs, and disease burden. Developing the TPP and evidence generation plan, early economic modeling will all contribute to charing the part to developing the right data required to support justifying the value and pricing of a product. Refine messaged as the product moves through the development stages. Conducting Advisory board meetings are useful for testing what	Possible					2	0.4	0	0
Phase2/3	Patient journey	HEOR	patient experience and healthcare service	points (unmet needs) and areas for improvement that	such as electronic health records, patient surveys.	data and messages resonates most with key stakeholders in terms of communicating the value of a product.							0.4	0	
Phase2/3	Value communication dossiers	Market Access	set through diagnosis, treatment and management.	 a new treatment might alleviate and potentially lead to a more seamless and positive patient/provider/payer experience. As part of the technology assessment US payers typically request an AMCP dossier for new 	and clinical trials, can be difficult. Sensitivity to sharing pre-approval information (e.g. clinical study recort, final label and launch pricino)	Ensure available evidence is collected (e.g. market research, SLR. ITC. model reports. clinical study report. ore-launch label.	Yes					2	0.4	U	0
			submission dossiers for Ex-US markets	Other HTA bodies have a different dossier format to communicate similar content, although it is usually more detailed.	Not having a fleshed-out value story.	value messages). At minimum, have a draft/pre-launch version developed that can be quickly updated once the price is official (frequently this	Possible					2	0.4	0	0

Phase3	studies	Market Access	understand the impact of product attributes have on price from the perspective of payers	demonstrated product attributes. Ability to optimize price and market share to maximize revenues.	of participants and can be very costly to execute due to development and programming of a pricing and	In randomizers of decision areas lowering other research tubies (e.g. CEA, Bill, Ashiroy beards, qualitative pricing research) to inform pricing decisions. In other cases, wait for the development program to reach Phase 3 and initial provida dita becomes available. At this point the investment risk is minimized by the product reaching the end- stage of development. Work with a vendor with excess to large numbers of HCPs and payers for recruitment, and with expertise of programming surveys for simple disk collection. Build in adeguards such as creening questions as part of the survey design to minimize risk of unrelable data.	Yes	2	0.4	0	O
Phase3/ Registration	Establish patient registry/Rik-evaluation strategy (post launch)	HEOR	term, real-world data on the safety, efficacy, and outcomes of CGTx or best supportive care or usual care.		Costly to design, implement and maintain, which for CGTx therapies could be a decade or more for follow-up.	Develop a study plan protocol and project plan that outlines the score, purpose/bject/ves, timeline, patient populations, interventions, outcomes. Assign responsibilities, personnel (incl advisory board), facilites, resource commitment, and contractors to execute and monitor the registry over time. Extract value from the registry from analysis of outcomes and publishing results.	Yes	2	0.4	0	0
Phase2/3	Pre-approval information exchange (PIE)	Market Access	educate Payers in the US about certain health care economic and scientific information about a new emerging products.	Market readiness tool that is used to facilitate early market access conversations with payers before Food and Drug Administration (FDA) approval.	Requires internal process for regulatory review and approval of materials to be shared externally with payers and other HCEI audiences. Sensitivity to share pricing information pre-launch.	Ensure here is evidentiary support for the HCEI to comply FDA regulations. Internal training/education on benefits and socialization of best practices on sharing pre-approval HECI as a way to overcome sensitivities to keeping information confidential until launch.	Possible	2	0.4	0	0

Total Composite Score



CGTx Commercialization Checklist for CIRM Grants

AAWG Supplemental Material April 30, 2025

Commercial activities



• Develop guideline commercialization activities for cell and gene therapy grantees from preclinical development to Biologics License Application (BLA)





Guideline activities may be used for:

- Internal CIRM or grantee education on what to expect for typical commercial activities and the timing of these activities during the development cycle
- CRIM to use commercial activities checklist for evaluation and awarding of grants



Pre-clinical – Commercial activities by level of importance

Activity Owner	Pre-clinical	Phase 1	Phase 2	Phase 3
Commercial	Intellectual property strategy Financial planning Briefing document Pre IND meeting Technology Transfer Regulatory pathway strategy Partnerships and collaborations			
Market Access	Marketlandscape assessment/market research Target product profile Reimbursement and market access strategy			
HEOR				
Medical Affairs	Proof of concept clinical trial design			



Color Key Nice to have

) Should have

Phase 1 – Commercial activities by level of importance


Activity Owner	Pre-clinical	Phase 1	Phase 2	Phase 3	
Commercial		Intellectual property strategy Financial planning			
		Technology Transfer			
		Regulatory pathway strategy Partnerships and collaborations			
		Early revenue and market access			
		Brand Strategy and positioning			
Market Access		Market landscape assessment/market research			
THINGE ACCOUNT		Target product profile Reimbursement and market access strategy			
		Market segmentation			
HEOR		Establish natural history of disease			
HLON		Cost of illness and standard of care			
		Quality of life assessment Early economic modeling			
		Briefing book			
		Proof of concept clinical trial design			
Medical Affairs		Scientific platform			



Color Key Nice to have

) Should have


Phase 2 - Commercial activities by level of importance



Color Key Nice to have

Should have

Phase 3 – Commercial activities by level of importance





Color Key Nice to have

Should have

Must have

© 2025 BlueRidge Life Sciences

Overview – Commercial activities by level of importance

Activity Owner	Pre-clinical	Phase 1	Phase 2	Phase 3
Commercial				Intellectual property strategy
	Briefing document Pre IND meeting			Financial planning
		Technology Transfer		
				Regulatory pathway strategy
				Partnerships and collaborations
			Early revenue and market access	Brand Strategy and positioning
				Establish (clinical/Payer) advisory boarc
				Market landscape assessment/market research
Market Access				Target product profile
				Reimbursement and market access strategy
				Market segmentation
				Value message Value communication dossier
				Quantitative pricing study
				Pre-approval information exchange (PIE)
HEOR			Establish natural history of disease	
				Cost of illness and standard of care
			Early economic modeling	Quality of life assessment
			Briefing bool	
				HTA ready cost-effectiveness analysis
				Patient journey
				Indirect treatment comparison
				Budget impact analysis
				Systematic literature review Establish patient registry
Madiaal Affaira		Proof of concept clinical trial design		
Medical Affairs				Scientific platform
BlueRidge		© 2025 BlueRidge Life Scier	nces	Confidential 8

Color Key Nice to have

) Should have

Must have

Commercial activities are grouped by activity owner, timing when the activity may commence and level of importance

Commercial activity owners and stages

Activity owner or functional area:

- Commercialization
- Market Access
- Health Economics and Outcomes Research (HEOR)
- Medical Affairs

Timing of activities are according to the development process:





• The importance of each activity is classified into three distinct categories and color coded accordingly:



Depending on the development stage, each activity will have a different level of priority and therefore scored accordingly

Scoring of activities by stage and functional area

• A priority factor is assigned to each activity:

Priority Level	Priority Factor
Not needed for stage	0
Low (Nice to have)	1
Medium (Should have)	2
High (Must Have)	3

• A raw score is assigned to each activity reflecting the status of the activity - **this factor is assigned by user**:

Raw Score
0
1
2
3
4
5

- In total there are 30 commercial activities expected to occur over the course of the development process
 - Many of the activities will span multiple development stages
 - Typically, the level of priority will increase as the asset progresses toward Phase 3 clinical trials and beyond
- Number of activities by development stage and functional area

	Pre- clinical	Phase 1	Phase 2	Phase 3
Commercial	6	7	7	6
Market Access	3	4	6	8
HEOR	0	5	8	8
Medical Affairs	1	2	1	1
Total by development stage	10	18	22	23

A total composite score is a cumulative result of the overall status of commercial activity

Commercial activity score weighting

• A composite commercial activity score is calculated using the following formula:

Composite commercial activity score:

$$\sum_{1}^{n} \left(\frac{(Priority \, Score)_{Activity \, n} \times (Raw \, Score)_{Ativity \, n}}{5} \right)$$

Note: the denominator is 5 so the top raw score assignment (raw score range 0-5) will be fully weighted



CIRM may use the composite scores to make funding decisions

• An Excel tool was developed to facilitate calculating the composite score for commercial activities

Directions: Cells in a light orange color (•) may be updated by user. All other cells to be left unchanged.

1.Select Stage of development (Cell B3).

2.Optional: Filter the respective development stage (column J, K, L or M) for nonblank cells.

3.Select Activity Score (Column N).

jment je	Pre-clinical			unchanged. 1) Select Stage of development (Cell B3). 2) Optional: Filter the respective development		Priority Level Ke	2		(Must Have)	1=Planned 2=In process/partially completed 3=Completed but needs updating/refresh				
Activity number	Timing of	Activity name	Activity Owner	Activity description	Supports	Pre-clinical	Timing of Phase 1	f Activity Phase 2	Phase 3	4=Completed in last 12 months Raw Score	Raw Score Weighting	Level of Priority	Weighted Score	
1	Pre-clinical	Intellectual property (IP) strategy	Commercialization	Developing a robust intellectual property	No					2	0.5	3	1.5	
2	Pre-clinical/1/2/3	Financial planning and	Commercialization	Estimate the anticipated required funds for	No					2	0.5	3	1.5	
3	Pre-clinical	Briefing document for-pre-IND	Commercialization	Summary of landscape assessment,	No					- 3 ² / ₄	1	3	3	
4	Pre-clinical/1/2/3	Market landscape	Market Access	Conducting detailed market research to	Possible					2	0.5	2	1	
5	Pre-clinical/1	Technology transfer and	Commercialization	Ensure that IP is protected as patents.	No					2	0.5	2	1	
6	Pre-clinical/1	Proof of concept clinical trial	Medical Affairs	Proof of concept (first in human) clinical trial	No					2	0.5	2	1	
7	Pre-clinical/1/2/3	Regulatory pathway strategy	Commercialization	Understand the options available by	No					2	0.5	1	0.5	
8	Pre-clinical/1/2	Partnerships and collaborations	Commercialization	Identifying potential strategic partnerships,	No					2	0.5	1	0.5	
9	Pre-clinical/1/2	Target Product Profile	Market Access	Outline by indication the attributes of the	No					2	0.5	1	0.5	
10	Pre-clinical/1/2/3	Reimbursement and market	Market Access	Planning for the product's reimbursement	Yes					2	0.5	1		
11	Phase 1/2	Establish the natural history of	HEOR	Track key outcomes that illustrates the	No					2	0.5	0		
12	Phase 1/2	Early revenue and market	Commercialization	Develop early market and revenue forecasts	Possible					2	0.5	0		Total
13	Phase 1/2/3	Brand strategy and positioning	Commercialization	Starting the process of brand development,	Possible					2	0.5	0		10000
14	Phase 1/2/3	Market segmentation	Market Access	Segregate potential customers (e.g.	Yes					2	0.5	0	\sim	
15	Phase 1/2/3	Cost of illness and standard of	HEOR	Design and conduct studies using real-world	No					2	0.5	0	Cor	npos
16	Phase1/2/3	Scientific platform	Medical Affairs	Develop a structure for the platform	No					2	0.5	0	00.	
17	Phase 1/2/3	Quality of life assessment	HEOR	Include HRQoL measures and utility weights	No					2	0.5	0	6	
18	Phase 1/2	Early economic modeling	HEOR	Develop an early cost-effectiveness model	No					2	0.5	0		Score
19	Phase 1/2	Briefing book	HEOR	Obtaining early scientific advice from health	No					2	0.5	0		
20	Phase 2/3	Establish (clinical and payer)	Commercialization	Identify key opinion leaders who could serve	Possible					2	0.5	0		aulat
21	Phase 2/3	Value message	Market Access	Develop value messages that communicate	Possible					2	0.5	0	cat	culat
22	Phase 2/3	Develop HTA ready Cost-	HEOR	Develop an HTA-ready global CEA that	No					2	0.5	0		
23	Phase 2/3	Patient journey	HEOR	Develop a detailed pathway documenting the	Yes					2	0.5	0	a t	hatta
24	Phase 2/3	Indirect treatment comparisons	HEOR	Conduct indirect treatment comparisons	No					2	0.5	0	a	botto
25	Phase 2/3	Value communication dossiers	Market Access	Development of AMCP dossier for the US	Possible					2	0.5	0		
26	Phase 3	Budget impact analysis	HEOR	Develop a user-friendly economic model that						2	0.5	0	of	shee
27	Phase 3	Quantitative pricing studies	Market Access	Conduct a robust conjoint analysis to	No					2	0.5	0	- 01	SHEE
28	Phase 3	Systematic literature review	HEOR	SLRs designed to understand the current	No					2	0.5	0		
29	Phase 3/	Establish patient registry/Risk-	HEOR	Develop a registry for patients to collect long						2	0.5	0	7/	
30	Phase 2/3	Pre-approval information	Market Access	Develop a presentation to proactively share	Possible					2	0.5	0		
tivity Co tal CRIN		ization Score for Applic	30 ation			10	18	22	23		Total Co Sco		11	





Access and Affordability Activity Details



Commercial Activity:

Reimbursement and market access strategy

Activity Description:

Planning for the product's reimbursement strategy by assessing the healthcare landscape, payer preferences, and pricing models.

Risk from Incomplete activity:

After a product receives market authorization, manufacturers must secure reimbursement to ensure market access. Although they can set list prices, actual access depends on a positive reimbursement decision following a costeffectiveness evaluation. Without a strong reimbursement strategy, insurers may limit access, resulting in financial losses, reduced adoption, and fewer patients benefiting from the therapy. If affordability isn't prioritized, high out-of-pocket costs can lead to poor adherence, treatment discontinuation, and negative public perception

Benefit	S	Barriers	C	Overcoming
 Early understanding product's economic health systems and stakeholders is imposuccessful adoption market. During clinical stage evidence generation product to ensure th will be available for r and reimbursement to justify value and p 	value to key ortant for in the s outline an plan for a e "right" data regulators authorities	 Accessing reliable, evidence including real-world data to inform pricing and reimbursement decisions can be challenging. Rare diseases may have additional challenges such as not having codes required for diagnosis and reimbursement. The treatment paradigm and reimbursement landscape may evolve by the time of launch. 	 exect produparad Condunde that r the p provitient of the TI Early unde prior Early unde prior Continet Continet refinet produport 	duct early pricing studies to rstand the price corridor night be acceptable from erspective of payers and ders given the attributes of PP. engagement with payers to rstand access hurdles (e.g authorizations); rstand impacts the new uct might have on provider ice in order to facilitate
Prioritybyphase	е			
Pre-clinical		This is a nice to have act in the Pre-clinical stage,		Color Key
Phase 1		should have by Phase 1 a must have in Phase 2 a	and	Not required
Phase 2		beyond.	-	Should have
Phase 3				Must have



Commercial Activity: Market segmentation	Benefits Key benefits include the ability to optimize marketing effort, enhance adoption and brand competitiveness. 	Barriers • Lack of data to be able to look at geography, demographics, and behaviors of the different stakeholders	Overcoming • Identify datasets that allow for identification of site of service and HCP prescribing behaviors.
Activity Description: Segregate potential customers (e.g., patients/providers/payers) into groups based on different characteristics (e.g., geography, demographics, behaviors, etc.).			
Risk from Incomplete Activity:			
Understanding market segments is essential for creating effective marketing strategies, product positioning, and messaging that connect with the right audience. Poor segmentation can weaken marketing impact and limit product adoption. It may also lead to wasted resources by targeting unprofitable segments or those with low unmet needs. Ultimately, this can result in mispricing and reduced profitability.	Priorityby phasePre-clinical)Phase 1)Phase 2)Phase 3)	This is a nice to have act in Phase 1, a should hav Phase 2 and a must have Phase 3.	e in Not required
Ridge	© 2025 BlueRidge Life Sciences		Confidential 14

Commercial Activity: Quantitative pricing studie

Activity Description:

Conduct a robust conjoint analysis to understand the impact of product attributes have on price from the perspective of payers and other key stakeholders.

Risk from Incomplete Activity:

Manufacturers generally have flexibility in setting drug prices, but market access depends on receiving a positive reimbursement decision after a costeffectiveness assessment. If a therapy is priced too high, insurers and health technology assessment (HTA) bodies may limit or deny reimbursement, restricting patient access. This limited access can lead to financial losses, reduced adoption, and prevent patients from receiving critical treatments. Additionally, poor affordability may result in low adherence, negative public perception, and limited market penetration.

	Benefi	ts	Barriers	Overcoming
es	 Understand the ma acceptable price giv demonstrated prod attributes. Ability to optimize p market share to ma revenues. 	ven uct price and	 Quantitative pricing studies require a large sample size of participants and can be very costly to execute due to development and programming of a pricing and attribute survey. In rare diseases there may not be sufficient participants to construct a large enough sample for the analysis. 	 In rare/ultrarare disease areas leverage other research studies (e.g. CEA, BIM, advisory boards, qualitative pricing research) to inform pricing decisions. In other cases, wait for the development program to reach Phase 3 and initial pivotal data becomes available. At this point the investment risk is minimized
nderstand the ce from the eholders.			 Risk of participant not being qualified for participating and leading to potential for erroneous data. 	 by the product reaching the end- stage of development. Work with a vendor with access to large numbers of HCPs and payers for recruitment, and with expertise of programming surveys for simple data collection. Build in safeguards such as
n setting on receiving				screening questions as part of the survey design to minimize risk of unreliable data.
a cost- priced too	Prioritybyphas	e		
essment ement,	Pre-clinical	\bigcirc	This is a must have in Pl 3.	
ccess can on, and	Phase 1	\bigcirc		Not required Nice to have
reatments. It in low	Phase 2	\bigcirc		Should have
and limited	Phase 3			Must have



Commercial Activity: Benefits Overcoming Barriers Patient journey Developing a patient journey Integrating and accessing data Engage with experts with helps identifying pain points from various sources, such as experience in integrating data (unmet needs) and areas for electronic health records. from diverse sources to improvement that a new patient surveys, and clinical streamline the process. treatment might alleviate and trials, can be difficult. potentially lead to a more seamless and positive patient/provider/payer experience. **Activity Description:** Develop a detailed pathway documenting the patient experience and healthcare service delivery from the point of a patient symptom on-set through diagnosis, treatment and management. **Risk from Incomplete Activity:** Without a well-developed patient journey, manufacturers risk missing important unmet needs **Priority by phase** of patients, providers, and payers, leading to suboptimal product development and support services. This is a should have activity Color Key Pre-clinical These gaps are missed opportunities to improve care in Phase 1 and a must have Not required delivery and address key challenges. Poor by Phase 2. Phase 1 understanding of the patient journey can also lead to Nice to have weak patient engagement and insufficient support Phase 2 Should have during treatment. As a result, patient access may Must have decline, ultimately affecting sales and product Phase 3 success.



Commercial Activity: Benefits Barriers Overcoming Establish patient registry/Risk-Enables monitoring of patients Aligning on the variables and Develop a study plan, protocol treated (or not treated) with a cell outcomes to collect. and project plan that outlines the evaluation strategy (post launch) or gene therapy over the long-Costly to design, implement and scope, purpose/objectives, term. Enables quantification and maintain, which for CGTx timeline, patient populations, validation of long-term treatment therapies could be a decade or interventions, outcomes. effects including duration of more for follow-up. Assign responsibilities, effect an other unknowns at the personnel (incl advisory board), time of launch. facilities, resource commitment, **Activity Description:** Regulatory authorities, such as and contractors to execute and the FDA and EMA, often mandate monitor the registry over time. the use of patient registries to Extract value from the registry Develop a registry for patients to collect long-term, from analysis of outcomes and monitor post-authorization real-world data on the safety, efficacy, and outcomes safety and efficacy of CGTx publishing results. drugs. Results may affect of CGTx or best supportive care or usual care. reimbursement decisions postlaunch. Can be used to continuously further the evidence base of the disease area by publishing **Risk from Incomplete Activity:** observed outcomes. CGTx clinical trials often involve long follow-up **Priority by phase** periods, leading to uncertainties around treatment outcomes such as effectiveness over time, This activity is usually a Color Key Pre-clinical tolerability, adverse events, and potential requirement by regulatory Not required complications. Many of these uncertainties could be authorities and initiated in Phase 1 addressed through extended patient monitoring. Nice to have Phase 3 However, without a robust registry, collecting long-Phase 2 Should have term real-world data becomes difficult, potentially

affecting post-launch reimbursement decisions, market access, and overall profitability.



Phase 3

Potential consequences of not executing commercial activity that supports access and affordability matters

Commercial activity supporting access/affordability	Consequences of not executing/failing activity
Reimbursement and market access strategy	 After a product gains market authorization by the FDA, EMA or other government agency the manufacturer subsequently needs to gain market access through securing reimbursement. While manufacturers have freedom in most cases to set their list prices, market access is granted via a positive reimbursement decision. Following a health technology appraisal where the cost-effectiveness is assessed, a reimbursement decision is made (also influenced by the price of the therapy). A poor market access and reimbursement strategy could lead to: Limited Market Access - insurers may not cover the drug or put access hurdles in place to limit access to sub-populations. In turn, limited access may lead to: Financial losses, sub-optimal revenues and adoption Patients may not be able to access potentially life-saving or disease modifying therapies. If affordability is not considered in the strategy it may impact: Patients may face a high financial strain leading to potential low-adherence, discontinuation and overall reduced market penetration. This may also result in poor public relations/perception if many patients are unable to afford the treatment.
Market segmentation	 Understanding market segments is critical to develop marketing strategies, product positioning and messaging that resonate with the key audience. Poor market segmentation may lead to: Reduced effectiveness of marketing campaigns, limited adoption Inefficient resource allocation, potentially marketing to segments that are not profitable, or where the unmet need is low. Low profitability from mis-pricing based on segments where the unmet need is low.
Patient journey	 Potential consequences of not having a well-developed patient journey could result in: Missing key patient, provider or payer unmet needs and sub-optimal product development including support services. These are opportunities to alleviate key pressure points and enhance the delivery of care across the continuum. Poor patient engagement, as the manufacturer may not communicate effectively or provide adequate support throughout the treatment process. These shortcomings may result in lower patient access and lower sales.



Potential consequences of not executing commercial activity that supports access and affordability matters (continued)

Commercial activity supporting access/affordability	Consequences of not executing/failing activity
Quantitative pricing studies	 While manufacturers have freedom in most cases to set their list prices, market access is granted via a positive reimbursement decision. Following a health technology appraisal where the cost-effectiveness is assessed, a reimbursement decision is made which is also influenced by the price of the therapy. A poor pricing strategy could lead to: Limited Market Access - insurers and HTA bodies may not grant reimbursement of the drug or put access hurdles in place to limit access to subpopulations where the unmet need is higher if the price is perceived as too high. In turn, limited access may lead to: Financial losses, sub-optimal revenues and adoption Patients may not be able to access potentially life-saving or disease modifying therapies. If affordability is not considered in the pricing strategy it may impact: Patients may face a high financial strain leading to potential low-adherence, discontinuation and overall reduced market penetration. This may also result in poor public relations/perception if many patients are unable to afford the treatment of if the therapy is not perceived to be value for money.
Establish patient registry/Risk-evaluation strategy (post launch)	 With CGTx clinical trials, due to the duration of follow-up there may be many uncertainties surrounding the outcomes of treatment (e.g. duration of effectiveness, tolerability and adverse events, development of complications etc.) which could be resolved by following patient for longer time periods. Without a robust registry, it becomes challenging to track long-term patient outcomes and gather real-world evidence, which may impact post-launch reimbursement, market access, and profitability.



Commercial Activity:

Early revenue and market forecast

Activity Description:

Develop early market and revenue forecasts using published evidence and qualitative primary research to understand the target population, peak market share, pricing and resulting revenues.

Benefits	Barriers	Overcoming
 These analysis are refined through out the development process and useful for negotiating potential licensing agreements. 	 Early forecasts will be rudimentary and largely based on crude hypothetical assumptions. More robust forecasts require an evidence-based understanding of the therapeutic area, available treatments, and where the asset fits in the clinical paradigm. Additionally, insights are needed to understand potential market shares and pricing assumptions. 	 Document key assumptions for early forecasts that are developed inhouse - these assumptions can be validated or refined during subsequent market research. Refine forecasts during the clinical development cycle by conducting robust secondary and primary market research using the TPP, understand where the product fits into the clinical paradigm, and gain insights from IDIs how the product will be perceived, potential market share and price range. Work with a market access/strategy consulting firm with expertise in developing forecasts.
Prioritybyphase		





Pre-clinical

Phase 1

Phase 2

Phase 3

This activity is nice to have in Phase 1, and a must have in Phase 2. In Phase 3 this should be updated with a pre-launch and launch forecast.




Commercial Activity:

Brand strategy and positioning

Activity Description:

Starting the process of brand development, including naming and positioning the drug in the marketplace. Understand how a product is differentiated in the market.

Benefits	Barriers	Overcoming
Lay the foundation for future value message development and what drivers of value are important to physicians, patients, payers and other stakeholders. Attract funding to support future development.	 Ealy product positioning will be largely hypothesis driven given the lack of available/robust evidence. Not understanding the products place in the clinical paradigm, potential value to patients, payers and providers. As the product nears the end of phase 3 clinical studies the branding will be dependent on completing the value message development activity. 	 Ensure market research is executed highlighting where the product fits into the clinical paradigm, and research with payers and providers will give insight into how the product will be perceived. Early in the development process establish a clear vision for the product outlining the unmet need and how the product will meet the need. By Phase 2/3, develop a brand strategy that identifies the target patients/providers, define the brand by what messages are to be communicated and positioning. This activity will require the value message development to be completed.





Commercial Activity: Benefits Barriers Overcoming Establish (clinical and payer) Clinical and payer KOLs offer Identifying KOLs and logistics of Develop logistics to follow expert advice as the identifying availability of multiple relevant company and local rules development program advisors with busy schedules. and laws when organizing an advisory board progresses through the clinical KOLs will need independent advisory board meeting. stages of development through contractor agreements (incl Consider outsourcing the commercial launch. CDAs) and the sponsor will need organization, logistics, agenda, to report on honoraria, travel, content development and accommodation and other meeting out-put expenses for compliance analysis/reporting to a **Activity Description:** contractor to assist unless inreasons. Shared materials typically house company support is require legal approval of content available. Identify key opinion leaders who could serve as and attendee ratios. advisers. Periodically seek feedback on clinical and Ensure the meeting meets objectives. economic evidence generation efforts. Periodically develop content for advisors to review and provide feedback to support the development **Priority by phase** This activity is should have Color Key Pre-clinical in Phase 2, and a must have Not required in Phase 3. Phase 1 Nice to have Phase 2 Should have Must have Phase 3



process.

Commercial Activity: Benefits Barriers Overcoming Marketlandscape Understanding the size of the The cost of preclinical market Perform in-house research market, potential customers, research can be perceived as reaching out to unmet needs, and potential prohibitively expensive and very providers/payers/advocacy assessment/market research barriers to entry. time consuming for small groups, and other key companies or start-ups and stakeholders. often there is only one person in Utilize free online industry the company with commercial reports to inform market responsibilities. Some perceive assessment. this activity as unnecessary in Consider minimal investment **Activity Description:** the pre-clinical stage. options for acquiring therapeutic area/industry market reports. Conducting detailed market research to assess the potential demand, competition, pricing strategies, and market gaps. **Priorityby phase** This is a should have activity Color Key Pre-clinical in the Pre-clinical stage and Not required a must have by Phase 1 Phase 1 Nice to have including maintenance/ updating through Phase 3. Phase 2 Should have Must have Phase 3



Commercial Activity:

Value message

Activity Description:

Develop value messages that communicate key drivers of value, which is supported by evidence that help differentiate a therapeutic in the marketplace.

Benefits

 Value messages help clearly communicate the benefits of a drug to various stakeholders, including regulators, payors, healthcare providers, and patients. This ensures that everyone understands the therapeutic and economic value of the drug. **Barriers**


Not incorporating key stakeholder input early in the evidence generation process (i.e. Phase I), so that Phase 2 and pivotal trials contain the right data to support a strong value proposition.

At the frontend of the development process a TPP is developed to begin formulating the key benefits and areas of differentiation for a drug. It is essential to have developed the key data to support each value message in parallel with the clinical development process.

Overcoming

- Conduct early market research (i.e. pre-clinical or Phase 1) into the market landscape, unmet needs, and disease burden.
- Developing the TPP and evidence generation plan, early economic modeling will all contribute to charting the path to developing the right data required to support justifying the value and pricing of a product.
- Refine messaged as the product moves through the development stages.
- Conducting Advisory board meetings are useful for testing what data and messages resonates most with key stakeholders in terms of communicating the value of a product.

Priorityby phase





Commercial Activity:

Value communication dossiers

Activity Description:

Development of AMCP dossier for the US (preapproval/final approved versions) and HTA submission dossiers for Ex-US markets.

Benefits	Barriers	Overcoming	
 As part of the technology assessment US payers typically request an AMCP dossier for new interventions. Other HTA bodies have a different dossier format to communicate similar content, although it is usually more detailed. 	 Sensitivity to sharing pre- approval information (fleshed- out clinical study report, final label and launch pricing) Not having a fleshed-out value story. Sensitivities to sharing sensitive data from clinical studies or delays in internal socialization of study data. 	 Ensure available evidence is collected (e.g. market research, SLR, ITC, model reports, clinical study report, pre-launch label, value messages). At minimum, have a draft/pre-launch version developed that can be quickly updated once the price is official (frequently this happens at launch). 	
Prioritybyphase			
	This is a should have in	Color Key	
Pre-clinical	Phase 2 and a must have		
Pre-clinical Phase 1	Phase 2 and a must have Phase 3.	-	
		e in Not required	



Commercial Activity:	Benefits	Barriers	Overcoming
Pre-approval information exchange (PIE)	 Market readiness tool that is used to facilitate early market access conversations with payers before Food and Drug Administration (FDA) approval. Helps prepare the market for anticipated place in therapy, pricing, clinical trial results, 	 Requires internal process for regulatory review and approval of materials to be shared externally with payers and other HCEI audiences. Sensitivity to share pricing information pre-launch. 	 Ensure there is evidentiary support for the HCEI to comply FDA regulations. Internal training/education on benefits and socialization of best practices on sharing pre- approval HECI as a way to overcome sensitivities to keeping
Activity Description:	potential indication, and anticipated timeline for FDA approval.		information confidential until launch.
Develop a presentation to proactively share and educate Payers in the US about certain health care economic and scientific information about a new emerging products.			
	Prioritybyphase		
	Pre-clinical	This is not a required act but is a should have in	ivity <u>Color Key</u> Not required
	Phase 1	Phase 3.	Nice to have
	Phase 2		Should have
	Phase 3		Must have



CIRM Access & Affordability Planning Toolkit Guidance for Applicants and Reviewers

Purpose

This **guidance document** is intended to help applicants and reviewers understand and apply the Access & Affordability (A&A) Toolkit developed by CIRM. The toolkit is designed to integrate structured access planning into CIRM's funding programs, ensuring that innovative therapies supported by CIRM can ultimately reach and benefit all Californians, especially underserved communities.

1. Overview of the Toolkit

The toolkit includes three main components:

A. Checklist

A structured list of commercialization-related activities that influence access and affordability. Activities are organized across four functional areas:

- Market Access
- Commercialization
- Health Economics and Outcomes Research (HEOR)
- Medical Affairs
- Each activity is tagged by:
- Development stage relevance (Preclinical to Phase 3/BLA)
- Priority: Must Have / Should Have / Nice to Have
- Timing: Pre-application prerequisite or post-award milestone

B. Evaluation Rubric

Used by reviewers to assess applicant progress on 12 selected activities most critical to access and affordability. Each activity is scored using:

- A Priority Factor based on its relevance to the development stage
- A Raw Score reflecting applicant progress (from "Not started" to "Completed in last 12 months")
- A Composite Score is calculated and used in review discussions and award monitoring

C. Guidance Documents (this document and future technical annexes)

These materials explain expectations, best practices, and examples of how to approach access and affordability planning at various stages of development.

2. Expectations for Applicants

Applicants are expected to:

- Review the Checklist to identify relevant activities for their development stage
- Include evidence of progress (or plans) in their application narrative or attachments
- Address Pre-requisite activities prior to application submission
- Propose Milestone-based activities to be completed during the course of the award

Key areas of focus include:

- Understanding the market and patient population
- Planning for reimbursement and access strategy
- Generating and communicating value
- Engaging key stakeholders (e.g., payers, providers, patient groups)
- Planning for long-term data generation (e.g., patient registries)

Where applicable, applicants should provide documentation of prior work (e.g., advisory board meeting summaries, pricing research, early economic modeling).

3. Use by Reviewers and CIRM Staff

Reviewers and staff will use the Evaluation Rubric to assess how well the proposed project incorporates access planning. Review will consider:

- The relevance of each activity to the development stage
- The quality and completeness of applicant work to date
- Alignment with the goal of equitable patient access in California

Rubric scores are used to guide review discussions and inform both:

- Initial funding decisions
- Ongoing award monitoring and milestone enforcement

4. Twelve Evaluated Activities in Accessibility and Affordability

The twelve rubric activities are defined in Annex A and detailed in Annex D milestone planning table at the end of this document.

5. Best Practices and Tips

Early engagement and documentation are critical. See Annex B for phase-appropriate examples and guidance.

6. Support and Resources

CIRM will provide:

- Webinars and office hours for applicants
- Access to templates and examples
- Clarification on expectations through program staff

Final versions of the checklist and rubric will be available in the PDEV and CLIN2 application materials.

7. Future Updates

This guidance will evolve based on feedback from applicants, reviewers, and program staff. Iterations may incorporate:

- Additional use cases
- Adjusted scoring models
- Integrated support from CIRM infrastructure (e.g., Alpha Clinics, CCCEs)

Annex A: Definitions of Checklist Activities

- Market landscape assessment / market research Conducting qualitative and quantitative research to assess market size, competition, demand, and barriers to entry.
- Reimbursement and market access strategy Planning for regulatory and payer approval by identifying pricing, coverage, and access considerations early in development.
- Early revenue and market forecast Estimating potential revenues based on target population, pricing assumptions, and market share projections.
- Brand strategy and positioning Developing a compelling brand identity, including name, message, and value proposition, aligned to stakeholder needs.
- Market segmentation
 Dividing the market into targetable groups based on geography, behaviors, or clinical characteristics.
- Establish (clinical and payer) advisory board
 Engaging KOLs and stakeholders to inform development plans and validate access strategies.
- Value message

Creating a concise, evidence-based statement communicating the product's therapeutic and economic benefit.

- Quantitative pricing studies Using data-driven techniques like conjoint analysis to estimate willingness to pay and acceptable price ranges.
- Value communication dossiers Preparing formal summaries of evidence (e.g., AMCP dossiers) for use with payers and HTA agencies.
- Establish patient registry
 Planning a post-marketing registry to monitor long-term safety, efficacy, and real-world outcomes.
- Patient journey

Mapping the full pathway from symptom onset to treatment, identifying barriers and unmet needs.

- **Pre-approval information exchange (PIE)** Preparing compliant information packets to inform payers ahead of FDA approval.

Annex B: Phase-Appropriate Examples and Best Practices

Preclinical Stage

- Conduct high-level market research using public sources
- Engage stakeholders to validate the target product profile (TPP)
- Outline early payer-relevant endpoints and unmet needs

Phase 1 Stage

- Begin structured interviews with providers or payers
- Create early financial models using published data
- Initiate pricing corridor exploration and stakeholder feedback

Phase 2 Stage

- Develop draft value messages and economic models
- Establishboards with diverse expert input
- Refine reimbursement strategies using payer interviews

Phase 3 Stage

- Execute PIE meetings to align with commercial readiness
- Launch patient registry planning and value dossier preparation
- Conduct formal quantitative pricing studies

Annex C: Milestone Planning Recommendations

Applicants should propose milestone-based activities based on their development stage. The following principles should guide planning:

- **Preclinical stage** activities should be focused on analysis, strategy development, and stakeholder engagement
- **Clinical stage** milestones should demonstrate execution of specific A&A activities (e.g., value message testing, pricing study initiation)
- Milestones should be specific, measurable, and time-bound
- When possible, link A&A milestones to technical or regulatory inflection points

Examples of appropriate milestones:

- Complete market segmentation analysis by Q4 2025
- Conduct pricing research interviews with 10 payers by end of Phase 2a
- Finalize and submit AMCP dossier within 3 months post-Phase 3 top-line data

Annex D: Phase-Appropriate Activities, Strategies, and Milestone Planning Table

Activity	Benefits	Strategy	Activity incorporated into award milestone?	Demonstrate activity progress to date in application?
Market landscape assessment/market research: Conducting detailed market research to assess the potential demand, competition, pricing strategies, and market gaps.	Understanding the size of the market, potential customers, unmet needs, and potential barriers to entry.	Perform in-house research reaching out to providers/payers/advocacy groups, and other key stakeholders. Utilize free online industry reports to inform market assessment. Consider minimal investment options for acquiring therapeutic area/industry market reports.	Yes- Preclinical	Yes- Phase 1
Reimbursement and market access strategy: Planning for the product's reimbursement strategy by assessing the healthcare landscape, payer preferences, and pricing models.	Early understanding of the product's economic value to health systems and key stakeholders is important for successful adoption in the market. During clinical stages outline an evidence generation plan for a product to ensure the "right" data will be available for regulators and reimbursement authorities to justify value and pricing.	Ensure market research is executed highlighting where the product fits into the clinical paradigm. Conduct early pricing studies to understand the price corridor that might be acceptable from the perspective of payers and providers given the attributes of the TPP. Early engagement with payers to understand access hurdles (e.g., prior authorizations); understand impacts the new product might have on provider practice in order to facilitate adoption. Continue monitoring and refinement of strategy as the product goes through the development process.	Yes- Phase 1	Yes- Phase 2
Early revenue and market forecast: Develop early market and revenue forecasts using published evidence and qualitative primary research to	These analyses are refined throughout the development process and useful for negotiating potential licensing agreements.	Document key assumptions for early forecasts that are developed in house - these assumptions can be validated or refined during subsequent market research.	Yes- Phase 1	Yes- Phase 2

understand the target population, peak market share, pricing and resulting revenues.		Refine forecasts during the clinical development cycle by conducting robust secondary and primary market research using the TPP, understand where the product fits into the clinical paradigm, and gain insights from IDIs regarding how the product will be perceived, potential market share and price range. Work with a market access/strategy consulting firm with expertise in developing forecasts.		
Brand strategy and positioning: Starting the process of brand development, including naming and positioning the drug in the marketplace. Understand how a product is differentiated in the market.	Lay the foundation for future value message development and what drivers of value are important to physicians, patients, payers and other stakeholders. Attract funding to support future development.	Ensure market research is executed highlighting where the product fits into the clinical paradigm; research with payers and providers will give insight into how the product will be perceived. Early in the development process, establish a clear vision for the product outlining the unmet need and how the product will meet the need. Later in the development process, develop a brand strategy that identifies the target patients/providers, define the brand by what messages are to be communicated, and lastly develop a positioning statement. This activity will require the value message development to be completed.	Yes- Phase 2	Yes- Phase 3
Market segmentation: Segregate potential customers (e.g., patients/providers/payers) into groups based on different characteristics (e.g., geography, demographics, behaviors, etc.).	Key benefits include the ability to optimize marketing effort, enhance adoption and brand competitiveness.	Identify datasets that allow for identification of site of service and HCP prescribing behaviors.	Yes- Phase 2	Yes- Phase 3

Establish (clinical and payer) advisory board: Identify key opinion leaders who could serve as advisers. Periodically seek feedback on clinical and economic evidence generation efforts. Periodically develop content for advisors to review and provide feedback to support the development process.	Clinical and payer KOLs offer expert advice as the development program progresses through the clinical stages of development through commercial launch.	Develop logistics to follow relevant company and local rules and laws when organizing an advisory board meeting. Consider outsourcing the organization, logistics, agenda, content development and meeting out-put analysis/reporting to a contractor to assist unless in-house company support is available	Yes- Phase 2	Yes- Phase 3
Value message: Develop value messages that communicate key drivers of value, which is supported by evidence that help differentiate a therapeutic in the marketplace.	Value messages help clearly communicate the benefits of a drug to various stakeholders, including regulators, payors, healthcare providers, and patients. This ensures that everyone understands the therapeutic and economic value of the drug.	Conduct early market research (i.e. pre- clinical or Phase 1) into the market landscape, unmet needs, and disease burden. Developing the TPP and evidence generation plan, early economic modeling will all contribute to charting the path to developing the right data required to support justifying the value and pricing of a product. Refine messaged as the product moves through the development stages. Conducting Advisory board meetings are useful for testing what data and messages resonate most with key stakeholders in terms of communicating the value of a product.	Yes- Phase 2	Yes- Phase 3
Quantitative pricing studies: Conduct a robust conjoint analysis to understand the impact of product attributes have on price from the	Understand the market acceptable price given demonstrated product attributes. Ability to optimize price and market share to maximize revenues.	In rare/ultrarare disease areas leverage other research studies (e.g. CEA, BIM, advisory boards, qualitative pricing research) to inform pricing decisions. In other cases, wait for the development program to reach Phase 3 and initial pivotal data becomes available. At this	Yes- Phase 2	Yes- Phase 3

perspective of payers and other key stakeholders.		 point the investment risk is minimized by the product reaching the end-stage of development. Work with a vendor with access to large numbers of HCPs and payers for recruitment, and with expertise of programming surveys for simple data collection. Build in safeguards such as screening questions as part of the survey design to 		
Value communication dossiers: Development of AMCP dossier for the US (pre- approval/final approved versions) and HTA submission dossiers for Ex- US markets	As part of the technology assessment US payers typically request an AMCP dossier for new interventions. Other HTA bodies have a different dossier format to communicate similar content, although it is usually more detailed.	 minimize risk of unreliable data. Ensure available evidence is collected (e.g. market research, SLR, ITC, model reports, clinical study report, pre-launch label, value messages). At minimum, have a draft/pre-launch version developed that can be quickly updated once the price is official (frequently this happens at launch). 	Yes- Phase 2	Yes- Phase 3
Establish patient registry/Risk-evaluation strategy (post launch): Develop a registry for patients to collect long-term, real-world data on the safety, efficacy, and outcomes of CGTx or best supportive care or usual care.	Enables monitoring of patients treated (or not treated) with a cell or gene therapy over the long- term. Enables quantification and validation of long-term treatment effects including duration of effect and other unknowns at the time of launch. Regulatory authorities, such as the FDA and EMA, often mandate the use of patient registries to monitor post- authorization safety and efficacy of CGTx drugs. Results may affect reimbursement decisions post-launch.	Develop a study plan, protocol and project plan that outline the scope, purpose/objectives, timeline, patient populations, interventions, outcomes. Assign responsibilities, personnel (incl advisory board), facilities, resource commitment, and contractors to execute and monitor the registry over time. Extract value from the registry from analysis of outcomes and publishing results.	Yes- Phase 2	Yes- Phase 3

Patient journey: Develop a detailed pathway documenting the patient experience and healthcare service delivery from the point of a patient symptom on-set through diagnosis, treatment and management.	Can be used to continuously further the evidence base of the disease area by publishing observed outcomes. Developing a patient journey helps identifying pain points (unmet needs) and areas for improvement that a new treatment might alleviate and potentially lead to a more seamless and positive patient/provider/payer experience.	Engage with experts with experience in integrating data from diverse sources to streamline the process.	Yes- Phase 3	No
Pre-approval information exchange (PIE): Develop a presentation to proactively share and educate Payers in the US about certain health care economic and scientific information about new emerging products.	Market readiness tool that is used to facilitate early market access conversations with payers before FDA approval. Helps prepare the market for anticipated place in therapy, pricing, clinical trial results, potential indication, and anticipated timeline for FDA approval.	Ensure there is evidentiary support for the HCEI to comply with FDA regulations. Internal training/education on benefits and socialization of best practices on sharing pre-approval HECI as a way to overcome sensitivities to keeping information confidential until launch.	Yes- Phase 3	Νο